ICU Medical, Inc. (ICUI) 10-Year Financial Performance & Capital Metrics

ICUI • • Industrial / General

HealthcareMedical InstrumentsInfusion & Drug Delivery SystemsIV Therapy & Access Products

AboutICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.Show more

Revenue $2.38B +5.4%
EBITDA $45M -82.0%
Net Income -$118M -296.9%
EPS (Diluted) -4.83 -292.7%
Gross Margin 34.62% +5.7%
EBITDA Margin 1.91% -82.9%
Operating Margin 1.8% +78.5%
Net Margin -4.94% -276.4%
ROE -5.76% -309.0%
ROIC 0.94% +96.9%
Debt/Equity 0.84 +4.1%
Interest Coverage 0.40 +81.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 13.5%

✗Weaknesses

✗Thin 5Y average net margin of 1.0%

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y22.65%

5Y13.47%

3Y21.86%

TTM-0.84%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM93.37%

EPS CAGR

10Y-

5Y-

3Y-

TTM93.22%

ROCE

10Y Avg4.79%

5Y Avg2.86%

3Y Avg0.07%

Latest1.14%

Peer Comparison

IV Therapy & Access Products

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TFXTeleflex Incorporated	4.62B	104.61	70.68	2.45%	-10.28%	-8.58%	11.02%	0.41
HAEHaemonetics Corporation	3.46B	74.00	22.36	3.95%	12.67%	19.81%	4.11%	1.49
ICUIICU Medical, Inc.	3.83B	155.12	-32.12	5.44%	-0.32%	-0.35%	3.26%	0.84

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	341.67M	379.37M	1.29B	1.4B	1.27B	1.27B	1.32B	2.28B	2.26B	2.38B
Revenue Growth %	0.1%	0.11%	2.41%	0.08%	-0.1%	0%	0.04%	0.73%	-0.01%	0.05%
Cost of Goods Sold+	160.87M	177.97M	866.52M	830.01M	794.34M	809.51M	824.82M	1.58B	1.52B	1.56B
COGS % of Revenue	0.47%	0.47%	0.67%	0.59%	0.63%	0.64%	0.63%	0.69%	0.67%	0.65%
Gross Profit+	180.8M	201.4M	426.1M	570.03M	471.86M	461.5M	491.49M	697.76M	739.87M	824.78M
Gross Margin %	0.53%	0.53%	0.33%	0.41%	0.37%	0.36%	0.37%	0.31%	0.33%	0.35%
Gross Profit Growth %	0.19%	0.11%	1.12%	0.34%	-0.17%	-0.02%	0.06%	0.42%	0.06%	0.11%
Operating Expenses+	98.93M	102.38M	355.21M	381.01M	364.5M	363.33M	368.25M	740.66M	717.05M	781.82M
OpEx % of Revenue	0.29%	0.27%	0.27%	0.27%	0.29%	0.29%	0.28%	0.32%	0.32%	0.33%
Selling, General & Admin	83.22M	89.43M	303.95M	328.15M	276.98M	283.95M	302.58M	608.35M	606.69M	638.76M
SG&A % of Revenue	0.24%	0.24%	0.24%	0.23%	0.22%	0.22%	0.23%	0.27%	0.27%	0.27%
Research & Development	15.71M	12.96M	51.25M	52.87M	48.61M	42.95M	47.5M	92.98M	85.34M	88.61M
R&D % of Revenue	0.05%	0.03%	0.04%	0.04%	0.04%	0.03%	0.04%	0.04%	0.04%	0.04%
Other Operating Expenses	0	767K	-2.48M	1.47M	38.91M	36.43M	18.16M	39.33M	25.01M	54.44M
Operating Income+	68.56M	82.94M	-15.08M	21.61M	107.36M	98.16M	123.25M	-42.9M	22.82M	42.96M
Operating Margin %	0.2%	0.22%	-0.01%	0.02%	0.08%	0.08%	0.09%	-0.02%	0.01%	0.02%
Operating Income Growth %	0.76%	0.21%	-1.18%	2.43%	3.97%	-0.09%	0.26%	-1.35%	1.53%	0.88%
EBITDA+	86.64M	101.99M	51.49M	96.35M	184.28M	193.01M	222.54M	192.25M	251.6M	45.4M
EBITDA Margin %	0.25%	0.27%	0.04%	0.07%	0.15%	0.15%	0.17%	0.08%	0.11%	0.02%
EBITDA Growth %	0.48%	0.18%	-0.5%	0.87%	0.91%	0.05%	0.15%	-0.14%	0.31%	-0.82%
D&A (Non-Cash Add-back)	18.07M	19.05M	66.57M	74.73M	76.92M	94.85M	99.29M	235.15M	228.77M	2.44M
EBIT	69.74M	85.28M	53.33M	197.16M	115.26M	99.25M	124.17M	-43.6M	24.43M	40.53M
Net Interest Income+	-39K	-118K	-2.05M	-709K	-549K	1.92M	1.98M	-66.38M	-95.22M	-95.75M
Interest Income	0	0	0	0	0	3.68M	2.84M	4.43M	7.51M	10.79M
Interest Expense	39K	118K	2.05M	709K	549K	1.75M	858K	70.81M	102.73M	106.54M
Other Income/Expense	1.13M	2.22M	64.58M	-7.38M	7.35M	-668K	-59K	-71.51M	-101.12M	-108.98M
Pretax Income+	69.7M	85.16M	51.28M	22.37M	114.71M	97.49M	123.19M	-114.41M	-78.3M	-66.01M
Pretax Margin %	0.2%	0.22%	0.04%	0.02%	0.09%	0.08%	0.09%	-0.05%	-0.03%	-0.03%
Income Tax+	24.71M	22.08M	-17.36M	-6.42M	13.67M	10.62M	20.05M	-40.12M	-48.64M	51.68M
Effective Tax Rate %	0.65%	0.74%	1.34%	1.29%	0.88%	0.89%	0.84%	0.65%	0.38%	1.78%
Net Income+	44.98M	63.08M	68.64M	28.79M	101.03M	86.87M	103.14M	-74.29M	-29.66M	-117.69M
Net Margin %	0.13%	0.17%	0.05%	0.02%	0.08%	0.07%	0.08%	-0.03%	-0.01%	-0.05%
Net Income Growth %	0.71%	0.4%	0.09%	-0.58%	2.51%	-0.14%	0.19%	-1.72%	0.6%	-2.97%
Net Income (Continuing)	44.98M	63.08M	68.64M	28.79M	101.03M	86.87M	103.14M	-74.29M	-29.66M	-117.69M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	2.73	3.66	3.29	1.33	4.69	4.02	4.74	-3.11	-1.23	-4.83
EPS Growth %	0.63%	0.34%	-0.1%	-0.6%	2.53%	-0.14%	0.18%	-1.66%	0.6%	-2.93%
EPS (Basic)	2.84	3.90	3.50	1.33	4.90	4.16	4.86	-3.11	-1.23	-4.83
Diluted Shares Outstanding	16.5M	17.25M	20.86M	21.6M	21.55M	21.59M	21.78M	23.87M	24.09M	24.39M
Basic Shares Outstanding	15.85M	16.17M	19.61M	21.6M	20.63M	20.91M	21.21M	23.87M	24.09M	24.39M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	505.01M	569.1M	864.66M	927.04M	882.2M	914.38M	1.03B	1.24B	1.22B	1.44B
Cash & Short-Term Investments	377.4M	445.08M	300.13M	382.11M	292.64M	410.78M	567.25M	213.01M	254.72M	308.57M
Cash Only	336.16M	445.08M	290.07M	344.78M	268.67M	396.1M	552.83M	208.78M	254.22M	308.57M
Short-Term Investments	41.23M	0	10.06M	37.33M	23.97M	14.69M	14.42M	4.22M	501K	0
Accounts Receivable	57.85M	59.11M	149.12M	196.44M	202.22M	127.77M	124.81M	246.9M	182.15M	202.7M
Days Sales Outstanding	61.8	56.87	42.11	51.21	58.29	36.69	34.61	39.53	29.43	31.06
Inventory	43.63M	49.26M	288.66M	311.16M	337.64M	314.93M	290.24M	696.01M	709.36M	584.68M
Days Inventory Outstanding	99	101.03	121.59	136.83	155.15	142	128.44	160.56	170.42	137.04
Other Current Assets	18.5M	13.99M	38.89M	21.1M	27.16M	25.24M	20.27M	43.05M	41.01M	321.42M
Total Non-Current Assets+	121.82M	135.59M	632.29M	658.36M	810.18M	849.32M	850.93M	3.28B	3.16B	2.76B
Property, Plant & Equipment	74.32M	85.7M	398.68M	432.64M	490.55M	513.2M	510.88M	713.58M	685.52M	499.3M
Fixed Asset Turnover	4.60x	4.43x	3.24x	3.24x	2.58x	2.48x	2.58x	3.20x	3.30x	4.77x
Goodwill	6.46M	5.58M	12.36M	11.2M	31.25M	33M	43.44M	1.45B	1.47B	1.43B
Intangible Assets	23.94M	22.38M	143.75M	133.42M	211.41M	197.23M	188.31M	982.77M	870.59M	740.79M
Long-Term Investments	-17.1M	-21.93M	14.58M	2.02M	0	12.97M	7.86M	3.69M	3.12M	8.76M
Other Non-Current Assets	17.1M	21.93M	38.14M	40.42M	48.98M	61.88M	57.83M	99.69M	88.19M	56.11M
Total Assets+	626.83M	704.69M	1.5B	1.59B	1.69B	1.76B	1.88B	4.52B	4.38B	4.2B
Asset Turnover	0.55x	0.54x	0.86x	0.88x	0.75x	0.72x	0.70x	0.50x	0.52x	0.57x
Asset Growth %	0.16%	0.12%	1.12%	0.06%	0.07%	0.04%	0.07%	1.4%	-0.03%	-0.04%
Total Current Liabilities+	42.62M	40.54M	210.29M	249.29M	248.47M	195.49M	200.78M	494.56M	481.84M	556.18M
Accounts Payable	13.67M	14.64M	78.23M	120.47M	128.63M	71.86M	81.13M	215.9M	150.03M	148.02M
Days Payables Outstanding	31.02	30.03	32.95	52.98	59.1	32.4	35.9	49.81	36.04	34.69
Short-Term Debt	0	0	0	0	0	9.29M	0	29.69M	51M	51M
Deferred Revenue (Current)	0	0	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	8.14M	12.28M	67.31M	58.61M	15.22M	53.51M	33.11M	42.93M	71.21M	103.17M
Current Ratio	11.85x	14.04x	4.11x	3.72x	3.55x	4.68x	5.13x	2.50x	2.53x	2.59x
Quick Ratio	10.83x	12.82x	2.74x	2.47x	2.19x	3.07x	3.68x	1.09x	1.06x	1.54x
Cash Conversion Cycle	129.78	127.88	130.75	135.07	154.33	146.29	127.14	150.28	163.81	133.4
Total Non-Current Liabilities+	4.34M	4M	88.41M	72.45M	66.67M	65.94M	63.93M	1.93B	1.77B	1.68B
Long-Term Debt	0	0	0	0	0	0	0	1.62B	1.58B	1.53B
Capital Lease Obligations	0	0	0	0	28.9M	43.41M	36.04M	62.77M	54.93M	43.11M
Deferred Tax Liabilities	1.37M	1.37M	1.49M	721K	2.09M	1.66M	1.49M	126.01M	55.87M	48.81M
Other Non-Current Liabilities	2.96M	2.63M	86.92M	71.73M	35.12M	19.67M	26.4M	102.46M	74.04M	49.69M
Total Liabilities	46.95M	44.53M	298.7M	321.74M	315.14M	261.43M	264.71M	2.43B	2.26B	2.24B
Total Debt+	0	0	0	0	36.26M	52.7M	45.05M	1.73B	1.7B	1.64B
Net Debt	-336.16M	-445.08M	-290.07M	-344.78M	-232.41M	-343.4M	-507.78M	1.53B	1.45B	1.33B
Debt / Equity	-	-	-	-	0.03x	0.04x	0.03x	0.83x	0.80x	0.84x
Debt / EBITDA	-	-	-	-	0.20x	0.27x	0.20x	9.02x	6.77x	36.16x
Net Debt / EBITDA	-3.88x	-4.36x	-5.63x	-3.58x	-1.26x	-1.78x	-2.28x	7.93x	5.76x	29.36x
Interest Coverage	1758.08x	702.89x	-7.37x	30.48x	195.56x	56.00x	143.64x	-0.61x	0.22x	0.40x
Total Equity+	579.87M	660.15M	1.2B	1.26B	1.38B	1.5B	1.62B	2.09B	2.12B	1.97B
Equity Growth %	0.14%	0.14%	0.82%	0.05%	0.09%	0.09%	0.08%	0.29%	0.02%	-0.07%
Book Value per Share	35.15	38.26	57.45	58.50	63.92	69.58	74.19	87.56	88.14	80.58
Total Shareholders' Equity	579.87M	660.15M	1.2B	1.26B	1.38B	1.5B	1.62B	2.09B	2.12B	1.97B
Common Stock	1.61M	1.63M	2.02M	2.05M	2.07M	2.11M	2.13M	2.4M	2.41M	2.45M
Retained Earnings	453.9M	516.98M	585.62M	620.75M	721.78M	808.65M	911.79M	837.5M	807.85M	690.16M
Treasury Stock	0	-14K	0	-95K	-157K	-39K	-27K	-243K	-262K	-92K
Accumulated OCI	-20.76M	-21.27M	-14.96M	-16.95M	-15.4M	-1.52M	-19.27M	-80.98M	-53.08M	-139.4M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	54.87M	89.94M	154.42M	160.22M	101.92M	222.75M	267.54M	-62.13M	166.2M	204.03M
Operating CF Margin %	0.16%	0.24%	0.12%	0.11%	0.08%	0.18%	0.2%	-0.03%	0.07%	0.09%
Operating CF Growth %	-0.1%	0.64%	0.72%	0.04%	-0.36%	1.19%	0.2%	-1.23%	3.68%	0.23%
Net Income	44.98M	63.08M	68.64M	28.79M	101.03M	86.87M	103.14M	-74.29M	-29.66M	-117.69M
Depreciation & Amortization	18.07M	19.05M	66.57M	74.73M	85.21M	94.85M	89.7M	235.15M	228.79M	240.86M
Stock-Based Compensation	12.83M	15.24M	19.35M	24.24M	21.92M	23.95M	27.34M	36.02M	40.56M	46.88M
Deferred Taxes	3.14M	-110K	-55.96M	20.27M	27.62M	3.77M	0	0	0	0
Other Non-Cash Items	1.67M	1.43M	-69K	37.58M	-22.23M	30.27M	32.33M	44.71M	62.1M	36.55M
Working Capital Changes	-25.83M	-8.76M	55.89M	-25.41M	-111.64M	-16.97M	15.04M	-303.73M	-135.6M	-2.57M
Change in Receivables	-20.52M	744K	-54.53M	-76.74M	-23.68M	78.05M	13.76M	-19.15M	48.63M	-46.84M
Change in Inventory	-8.34M	-5.5M	181.7M	-21.77M	-25M	19.2M	20.82M	-201.09M	-6.08M	16.83M
Change in Payables	3.12M	-463K	46.65M	23.27M	-2.7M	-46.41M	2.35M	37.47M	-68.3M	12.53M
Cash from Investing+	-11.24M	16.28M	-266.87M	-103.37M	-166.89M	-98.14M	-90.69M	-1.91B	-87.95M	-88.96M
Capital Expenditures	-13.94M	-24.55M	-79.68M	-100.78M	-106.04M	-100.39M	-68.54M	-90.31M	-83.89M	-79.37M
CapEx % of Revenue	0.04%	0.06%	0.06%	0.07%	0.08%	0.08%	0.05%	0.04%	0.04%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	3.59M	3.27M	5.21M	13.77M	33K	14.56M	-12.41M	-8.03M	-8.28M	-10.09M
Cash from Financing+	25.01M	2.47M	-44.35M	8.02M	-10.91M	-40K	-16.87M	1.64B	-35.98M	-55.8M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	26.53M	19.71M	34.71M	14.28M	0	0	-16.26M	-4.28M	0	-2.6M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	40.93M	65.39M	74.74M	59.44M	-4.12M	122.36M	186.37M	-161.46M	72.53M	124.66M
FCF Margin %	0.12%	0.17%	0.06%	0.04%	-0%	0.1%	0.14%	-0.07%	0.03%	0.05%
FCF Growth %	-0.05%	0.6%	0.14%	-0.2%	-1.07%	30.69%	0.52%	-1.87%	1.45%	0.72%
FCF per Share	2.48	3.79	3.58	2.75	-0.19	5.67	8.56	-6.76	3.01	5.11
FCF Conversion (FCF/Net Income)	1.22x	1.43x	2.25x	5.56x	1.01x	2.56x	2.59x	0.84x	-5.60x	-1.73x
Interest Paid	39K	118K	2.05M	709K	549K	1.75M	858K	63.71M	95.91M	99.72M
Taxes Paid	23M	21.1M	5.11M	12.6M	9.68M	31.63M	19.56M	27.5M	35.81M	25.25M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	8.27%	10.17%	7.39%	2.34%	7.65%	6.03%	6.61%	-4.01%	-1.41%	-5.76%
Return on Invested Capital (ROIC)	21.6%	27.12%	-2.01%	1.77%	7.8%	6.39%	8.15%	-1.36%	0.48%	0.94%
Gross Margin	52.92%	53.09%	32.96%	40.72%	37.27%	36.31%	37.34%	30.6%	32.75%	34.62%
Net Margin	13.17%	16.63%	5.31%	2.06%	7.98%	6.83%	7.84%	-3.26%	-1.31%	-4.94%
Debt / Equity	-	-	-	-	0.03x	0.04x	0.03x	0.83x	0.80x	0.84x
Interest Coverage	1758.08x	702.89x	-7.37x	30.48x	195.56x	56.00x	143.64x	-0.61x	0.22x	0.40x
FCF Conversion	1.22x	1.43x	2.25x	5.56x	1.01x	2.56x	2.59x	0.84x	-5.60x	-1.73x
Revenue Growth	10.48%	11.04%	240.72%	8.31%	-9.56%	0.38%	3.56%	73.21%	-0.92%	5.44%

Revenue by Segment

	2014	2015	2017	2018	2019	2020	2021	2022	2023	2024
Infusion Consumables	-	-	-	483.04M	477.61M	473.74M	555.19M	566.62M	969.13M	1.04B
Infusion Consumables Growth	-	-	-	-	-1.12%	-0.81%	17.19%	2.06%	71.04%	7.20%
Vital Care	-	-	-	-	-	-	-	284.61M	660.95M	690.77M
Vital Care Growth	-	-	-	-	-	-	-	-	132.23%	4.51%
Infusion Systems	-	-	-	355.48M	328.28M	359.69M	352.32M	351.08M	629.04M	652.41M
Infusion Systems Growth	-	-	-	-	-7.65%	9.57%	-2.05%	-0.35%	79.17%	3.71%
IV Solutions	-	-	-	507.99M	414.97M	388.97M	359.48M	363.47M	-	-
IV Solutions Growth	-	-	-	-	-18.31%	-6.27%	-7.58%	1.11%	-	-
Infusion Consumables-Smiths Medical	-	-	-	-	-	-	-	340.12M	-	-
Infusion Consumables-Smiths Medical Growth	-	-	-	-	-	-	-	-	-	-
Vascular Access	-	-	-	-	-	-	-	326.76M	-	-
Vascular Access Growth	-	-	-	-	-	-	-	-	-	-
Critical Care	-	-	-	53.53M	45.34M	48.6M	49.32M	47.33M	-	-
Critical Care Growth	-	-	-	-	-15.30%	7.19%	1.48%	-4.04%	-	-
Other Revenue	1.25M	1.16M	-	-	-	-	-	-	-	-
Other Revenue Growth	-	-7.33%	-	-	-	-	-	-	-	-
Sales Revenue, Net	-	341.67M	-	-	-	-	-	-	-	-
Sales Revenue, Net Growth	-	-	-	-	-	-	-	-	-	-
Infusion Therapy	215.98M	244.75M	-	-	-	-	-	-	-	-
Infusion Therapy Growth	-	13.32%	-	-	-	-	-	-	-	-
Critical Care Revenue	55.07M	54.31M	-	-	-	-	-	-	-	-
Critical Care Revenue Growth	-	-1.38%	-	-	-	-	-	-	-	-
Oncology Revenue	36.95M	41.45M	-	-	-	-	-	-	-	-
Oncology Revenue Growth	-	12.17%	-	-	-	-	-	-	-	-

Revenue by Geography

	2014	2015	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	979.94M	1.05B	923.34M	910.63M	941.81M	1.46B	1.44B	1.53B
UNITED STATES Growth	-	-	-	7.63%	-12.45%	-1.38%	3.42%	55.03%	-1.37%	6.39%
EMEA	-	-	-	134.36M	130.53M	132.76M	147.49M	367.41M	373.57M	393.53M
EMEA Growth	-	-	-	-	-2.85%	1.71%	11.09%	149.11%	1.68%	5.34%
Asia Pacific	-	-	54.47M	-	-	-	-	257.21M	241.7M	232M
Asia Pacific Growth	-	-	-	-	-	-	-	-	-6.03%	-4.01%
Other foreign countries	-	-	30.18M	211M	212.34M	227.61M	227.01M	195.31M	203.84M	223.59M
Other foreign countries Growth	-	-	-	599.03%	0.64%	7.20%	-0.26%	-13.96%	4.37%	9.69%
Foreign	-	-	312.68M	345.36M	342.87M	-	-	-	-	-
Foreign Growth	-	-	-	10.45%	-0.72%	-	-	-	-	-
Europe	-	-	100.42M	-	-	-	-	-	-	-
Europe Growth	-	-	-	-	-	-	-	-	-	-
CANADA	-	-	69.75M	-	-	-	-	-	-	-
CANADA Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

ICU Medical, Inc. (ICUI) reported $2.32B in revenue for fiscal year 2024. This represents a 668% increase from $302.2M in 2011.

ICU Medical, Inc. (ICUI) grew revenue by 5.4% over the past year. This is steady growth.

ICU Medical, Inc. (ICUI) reported a net loss of $7.4M for fiscal year 2024.

Dividend & Returns

ICU Medical, Inc. (ICUI) has a return on equity (ROE) of -5.8%. Negative ROE indicates the company is unprofitable.

ICU Medical, Inc. (ICUI) generated $67.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

ICU Medical, Inc. (ICUI) 10-Year Financial Performance & Capital Metrics

ICUI • • Industrial / General

HealthcareMedical InstrumentsInfusion & Drug Delivery SystemsIV Therapy & Access Products

Revenue $2.38B +5.4%
EBITDA $45M -82.0%
Net Income -$118M -296.9%
EPS (Diluted) -4.83 -292.7%
Gross Margin 34.62% +5.7%
EBITDA Margin 1.91% -82.9%
Operating Margin 1.8% +78.5%
Net Margin -4.94% -276.4%
ROE -5.76% -309.0%
ROIC 0.94% +96.9%
Debt/Equity 0.84 +4.1%
Interest Coverage 0.40 +81.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 13.5%

✗Weaknesses

✗Thin 5Y average net margin of 1.0%

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y22.65%

5Y13.47%

3Y21.86%

TTM-0.84%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM93.37%

EPS CAGR

10Y-

5Y-

3Y-

TTM93.22%

ROCE

10Y Avg4.79%

5Y Avg2.86%

3Y Avg0.07%

Latest1.14%

Peer Comparison

IV Therapy & Access Products

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TFXTeleflex Incorporated	4.62B	104.61	70.68	2.45%	-10.28%	-8.58%	11.02%	0.41
HAEHaemonetics Corporation	3.46B	74.00	22.36	3.95%	12.67%	19.81%	4.11%	1.49
ICUIICU Medical, Inc.	3.83B	155.12	-32.12	5.44%	-0.32%	-0.35%	3.26%	0.84

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	341.67M	379.37M	1.29B	1.4B	1.27B	1.27B	1.32B	2.28B	2.26B	2.38B
Revenue Growth %	0.1%	0.11%	2.41%	0.08%	-0.1%	0%	0.04%	0.73%	-0.01%	0.05%
Cost of Goods Sold+	160.87M	177.97M	866.52M	830.01M	794.34M	809.51M	824.82M	1.58B	1.52B	1.56B
COGS % of Revenue	0.47%	0.47%	0.67%	0.59%	0.63%	0.64%	0.63%	0.69%	0.67%	0.65%
Gross Profit+	180.8M	201.4M	426.1M	570.03M	471.86M	461.5M	491.49M	697.76M	739.87M	824.78M
Gross Margin %	0.53%	0.53%	0.33%	0.41%	0.37%	0.36%	0.37%	0.31%	0.33%	0.35%
Gross Profit Growth %	0.19%	0.11%	1.12%	0.34%	-0.17%	-0.02%	0.06%	0.42%	0.06%	0.11%
Operating Expenses+	98.93M	102.38M	355.21M	381.01M	364.5M	363.33M	368.25M	740.66M	717.05M	781.82M
OpEx % of Revenue	0.29%	0.27%	0.27%	0.27%	0.29%	0.29%	0.28%	0.32%	0.32%	0.33%
Selling, General & Admin	83.22M	89.43M	303.95M	328.15M	276.98M	283.95M	302.58M	608.35M	606.69M	638.76M
SG&A % of Revenue	0.24%	0.24%	0.24%	0.23%	0.22%	0.22%	0.23%	0.27%	0.27%	0.27%
Research & Development	15.71M	12.96M	51.25M	52.87M	48.61M	42.95M	47.5M	92.98M	85.34M	88.61M
R&D % of Revenue	0.05%	0.03%	0.04%	0.04%	0.04%	0.03%	0.04%	0.04%	0.04%	0.04%
Other Operating Expenses	0	767K	-2.48M	1.47M	38.91M	36.43M	18.16M	39.33M	25.01M	54.44M
Operating Income+	68.56M	82.94M	-15.08M	21.61M	107.36M	98.16M	123.25M	-42.9M	22.82M	42.96M
Operating Margin %	0.2%	0.22%	-0.01%	0.02%	0.08%	0.08%	0.09%	-0.02%	0.01%	0.02%
Operating Income Growth %	0.76%	0.21%	-1.18%	2.43%	3.97%	-0.09%	0.26%	-1.35%	1.53%	0.88%
EBITDA+	86.64M	101.99M	51.49M	96.35M	184.28M	193.01M	222.54M	192.25M	251.6M	45.4M
EBITDA Margin %	0.25%	0.27%	0.04%	0.07%	0.15%	0.15%	0.17%	0.08%	0.11%	0.02%
EBITDA Growth %	0.48%	0.18%	-0.5%	0.87%	0.91%	0.05%	0.15%	-0.14%	0.31%	-0.82%
D&A (Non-Cash Add-back)	18.07M	19.05M	66.57M	74.73M	76.92M	94.85M	99.29M	235.15M	228.77M	2.44M
EBIT	69.74M	85.28M	53.33M	197.16M	115.26M	99.25M	124.17M	-43.6M	24.43M	40.53M
Net Interest Income+	-39K	-118K	-2.05M	-709K	-549K	1.92M	1.98M	-66.38M	-95.22M	-95.75M
Interest Income	0	0	0	0	0	3.68M	2.84M	4.43M	7.51M	10.79M
Interest Expense	39K	118K	2.05M	709K	549K	1.75M	858K	70.81M	102.73M	106.54M
Other Income/Expense	1.13M	2.22M	64.58M	-7.38M	7.35M	-668K	-59K	-71.51M	-101.12M	-108.98M
Pretax Income+	69.7M	85.16M	51.28M	22.37M	114.71M	97.49M	123.19M	-114.41M	-78.3M	-66.01M
Pretax Margin %	0.2%	0.22%	0.04%	0.02%	0.09%	0.08%	0.09%	-0.05%	-0.03%	-0.03%
Income Tax+	24.71M	22.08M	-17.36M	-6.42M	13.67M	10.62M	20.05M	-40.12M	-48.64M	51.68M
Effective Tax Rate %	0.65%	0.74%	1.34%	1.29%	0.88%	0.89%	0.84%	0.65%	0.38%	1.78%
Net Income+	44.98M	63.08M	68.64M	28.79M	101.03M	86.87M	103.14M	-74.29M	-29.66M	-117.69M
Net Margin %	0.13%	0.17%	0.05%	0.02%	0.08%	0.07%	0.08%	-0.03%	-0.01%	-0.05%
Net Income Growth %	0.71%	0.4%	0.09%	-0.58%	2.51%	-0.14%	0.19%	-1.72%	0.6%	-2.97%
Net Income (Continuing)	44.98M	63.08M	68.64M	28.79M	101.03M	86.87M	103.14M	-74.29M	-29.66M	-117.69M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	2.73	3.66	3.29	1.33	4.69	4.02	4.74	-3.11	-1.23	-4.83
EPS Growth %	0.63%	0.34%	-0.1%	-0.6%	2.53%	-0.14%	0.18%	-1.66%	0.6%	-2.93%
EPS (Basic)	2.84	3.90	3.50	1.33	4.90	4.16	4.86	-3.11	-1.23	-4.83
Diluted Shares Outstanding	16.5M	17.25M	20.86M	21.6M	21.55M	21.59M	21.78M	23.87M	24.09M	24.39M
Basic Shares Outstanding	15.85M	16.17M	19.61M	21.6M	20.63M	20.91M	21.21M	23.87M	24.09M	24.39M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	505.01M	569.1M	864.66M	927.04M	882.2M	914.38M	1.03B	1.24B	1.22B	1.44B
Cash & Short-Term Investments	377.4M	445.08M	300.13M	382.11M	292.64M	410.78M	567.25M	213.01M	254.72M	308.57M
Cash Only	336.16M	445.08M	290.07M	344.78M	268.67M	396.1M	552.83M	208.78M	254.22M	308.57M
Short-Term Investments	41.23M	0	10.06M	37.33M	23.97M	14.69M	14.42M	4.22M	501K	0
Accounts Receivable	57.85M	59.11M	149.12M	196.44M	202.22M	127.77M	124.81M	246.9M	182.15M	202.7M
Days Sales Outstanding	61.8	56.87	42.11	51.21	58.29	36.69	34.61	39.53	29.43	31.06
Inventory	43.63M	49.26M	288.66M	311.16M	337.64M	314.93M	290.24M	696.01M	709.36M	584.68M
Days Inventory Outstanding	99	101.03	121.59	136.83	155.15	142	128.44	160.56	170.42	137.04
Other Current Assets	18.5M	13.99M	38.89M	21.1M	27.16M	25.24M	20.27M	43.05M	41.01M	321.42M
Total Non-Current Assets+	121.82M	135.59M	632.29M	658.36M	810.18M	849.32M	850.93M	3.28B	3.16B	2.76B
Property, Plant & Equipment	74.32M	85.7M	398.68M	432.64M	490.55M	513.2M	510.88M	713.58M	685.52M	499.3M
Fixed Asset Turnover	4.60x	4.43x	3.24x	3.24x	2.58x	2.48x	2.58x	3.20x	3.30x	4.77x
Goodwill	6.46M	5.58M	12.36M	11.2M	31.25M	33M	43.44M	1.45B	1.47B	1.43B
Intangible Assets	23.94M	22.38M	143.75M	133.42M	211.41M	197.23M	188.31M	982.77M	870.59M	740.79M
Long-Term Investments	-17.1M	-21.93M	14.58M	2.02M	0	12.97M	7.86M	3.69M	3.12M	8.76M
Other Non-Current Assets	17.1M	21.93M	38.14M	40.42M	48.98M	61.88M	57.83M	99.69M	88.19M	56.11M
Total Assets+	626.83M	704.69M	1.5B	1.59B	1.69B	1.76B	1.88B	4.52B	4.38B	4.2B
Asset Turnover	0.55x	0.54x	0.86x	0.88x	0.75x	0.72x	0.70x	0.50x	0.52x	0.57x
Asset Growth %	0.16%	0.12%	1.12%	0.06%	0.07%	0.04%	0.07%	1.4%	-0.03%	-0.04%
Total Current Liabilities+	42.62M	40.54M	210.29M	249.29M	248.47M	195.49M	200.78M	494.56M	481.84M	556.18M
Accounts Payable	13.67M	14.64M	78.23M	120.47M	128.63M	71.86M	81.13M	215.9M	150.03M	148.02M
Days Payables Outstanding	31.02	30.03	32.95	52.98	59.1	32.4	35.9	49.81	36.04	34.69
Short-Term Debt	0	0	0	0	0	9.29M	0	29.69M	51M	51M
Deferred Revenue (Current)	0	0	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	8.14M	12.28M	67.31M	58.61M	15.22M	53.51M	33.11M	42.93M	71.21M	103.17M
Current Ratio	11.85x	14.04x	4.11x	3.72x	3.55x	4.68x	5.13x	2.50x	2.53x	2.59x
Quick Ratio	10.83x	12.82x	2.74x	2.47x	2.19x	3.07x	3.68x	1.09x	1.06x	1.54x
Cash Conversion Cycle	129.78	127.88	130.75	135.07	154.33	146.29	127.14	150.28	163.81	133.4
Total Non-Current Liabilities+	4.34M	4M	88.41M	72.45M	66.67M	65.94M	63.93M	1.93B	1.77B	1.68B
Long-Term Debt	0	0	0	0	0	0	0	1.62B	1.58B	1.53B
Capital Lease Obligations	0	0	0	0	28.9M	43.41M	36.04M	62.77M	54.93M	43.11M
Deferred Tax Liabilities	1.37M	1.37M	1.49M	721K	2.09M	1.66M	1.49M	126.01M	55.87M	48.81M
Other Non-Current Liabilities	2.96M	2.63M	86.92M	71.73M	35.12M	19.67M	26.4M	102.46M	74.04M	49.69M
Total Liabilities	46.95M	44.53M	298.7M	321.74M	315.14M	261.43M	264.71M	2.43B	2.26B	2.24B
Total Debt+	0	0	0	0	36.26M	52.7M	45.05M	1.73B	1.7B	1.64B
Net Debt	-336.16M	-445.08M	-290.07M	-344.78M	-232.41M	-343.4M	-507.78M	1.53B	1.45B	1.33B
Debt / Equity	-	-	-	-	0.03x	0.04x	0.03x	0.83x	0.80x	0.84x
Debt / EBITDA	-	-	-	-	0.20x	0.27x	0.20x	9.02x	6.77x	36.16x
Net Debt / EBITDA	-3.88x	-4.36x	-5.63x	-3.58x	-1.26x	-1.78x	-2.28x	7.93x	5.76x	29.36x
Interest Coverage	1758.08x	702.89x	-7.37x	30.48x	195.56x	56.00x	143.64x	-0.61x	0.22x	0.40x
Total Equity+	579.87M	660.15M	1.2B	1.26B	1.38B	1.5B	1.62B	2.09B	2.12B	1.97B
Equity Growth %	0.14%	0.14%	0.82%	0.05%	0.09%	0.09%	0.08%	0.29%	0.02%	-0.07%
Book Value per Share	35.15	38.26	57.45	58.50	63.92	69.58	74.19	87.56	88.14	80.58
Total Shareholders' Equity	579.87M	660.15M	1.2B	1.26B	1.38B	1.5B	1.62B	2.09B	2.12B	1.97B
Common Stock	1.61M	1.63M	2.02M	2.05M	2.07M	2.11M	2.13M	2.4M	2.41M	2.45M
Retained Earnings	453.9M	516.98M	585.62M	620.75M	721.78M	808.65M	911.79M	837.5M	807.85M	690.16M
Treasury Stock	0	-14K	0	-95K	-157K	-39K	-27K	-243K	-262K	-92K
Accumulated OCI	-20.76M	-21.27M	-14.96M	-16.95M	-15.4M	-1.52M	-19.27M	-80.98M	-53.08M	-139.4M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	54.87M	89.94M	154.42M	160.22M	101.92M	222.75M	267.54M	-62.13M	166.2M	204.03M
Operating CF Margin %	0.16%	0.24%	0.12%	0.11%	0.08%	0.18%	0.2%	-0.03%	0.07%	0.09%
Operating CF Growth %	-0.1%	0.64%	0.72%	0.04%	-0.36%	1.19%	0.2%	-1.23%	3.68%	0.23%
Net Income	44.98M	63.08M	68.64M	28.79M	101.03M	86.87M	103.14M	-74.29M	-29.66M	-117.69M
Depreciation & Amortization	18.07M	19.05M	66.57M	74.73M	85.21M	94.85M	89.7M	235.15M	228.79M	240.86M
Stock-Based Compensation	12.83M	15.24M	19.35M	24.24M	21.92M	23.95M	27.34M	36.02M	40.56M	46.88M
Deferred Taxes	3.14M	-110K	-55.96M	20.27M	27.62M	3.77M	0	0	0	0
Other Non-Cash Items	1.67M	1.43M	-69K	37.58M	-22.23M	30.27M	32.33M	44.71M	62.1M	36.55M
Working Capital Changes	-25.83M	-8.76M	55.89M	-25.41M	-111.64M	-16.97M	15.04M	-303.73M	-135.6M	-2.57M
Change in Receivables	-20.52M	744K	-54.53M	-76.74M	-23.68M	78.05M	13.76M	-19.15M	48.63M	-46.84M
Change in Inventory	-8.34M	-5.5M	181.7M	-21.77M	-25M	19.2M	20.82M	-201.09M	-6.08M	16.83M
Change in Payables	3.12M	-463K	46.65M	23.27M	-2.7M	-46.41M	2.35M	37.47M	-68.3M	12.53M
Cash from Investing+	-11.24M	16.28M	-266.87M	-103.37M	-166.89M	-98.14M	-90.69M	-1.91B	-87.95M	-88.96M
Capital Expenditures	-13.94M	-24.55M	-79.68M	-100.78M	-106.04M	-100.39M	-68.54M	-90.31M	-83.89M	-79.37M
CapEx % of Revenue	0.04%	0.06%	0.06%	0.07%	0.08%	0.08%	0.05%	0.04%	0.04%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	3.59M	3.27M	5.21M	13.77M	33K	14.56M	-12.41M	-8.03M	-8.28M	-10.09M
Cash from Financing+	25.01M	2.47M	-44.35M	8.02M	-10.91M	-40K	-16.87M	1.64B	-35.98M	-55.8M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	26.53M	19.71M	34.71M	14.28M	0	0	-16.26M	-4.28M	0	-2.6M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	40.93M	65.39M	74.74M	59.44M	-4.12M	122.36M	186.37M	-161.46M	72.53M	124.66M
FCF Margin %	0.12%	0.17%	0.06%	0.04%	-0%	0.1%	0.14%	-0.07%	0.03%	0.05%
FCF Growth %	-0.05%	0.6%	0.14%	-0.2%	-1.07%	30.69%	0.52%	-1.87%	1.45%	0.72%
FCF per Share	2.48	3.79	3.58	2.75	-0.19	5.67	8.56	-6.76	3.01	5.11
FCF Conversion (FCF/Net Income)	1.22x	1.43x	2.25x	5.56x	1.01x	2.56x	2.59x	0.84x	-5.60x	-1.73x
Interest Paid	39K	118K	2.05M	709K	549K	1.75M	858K	63.71M	95.91M	99.72M
Taxes Paid	23M	21.1M	5.11M	12.6M	9.68M	31.63M	19.56M	27.5M	35.81M	25.25M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	8.27%	10.17%	7.39%	2.34%	7.65%	6.03%	6.61%	-4.01%	-1.41%	-5.76%
Return on Invested Capital (ROIC)	21.6%	27.12%	-2.01%	1.77%	7.8%	6.39%	8.15%	-1.36%	0.48%	0.94%
Gross Margin	52.92%	53.09%	32.96%	40.72%	37.27%	36.31%	37.34%	30.6%	32.75%	34.62%
Net Margin	13.17%	16.63%	5.31%	2.06%	7.98%	6.83%	7.84%	-3.26%	-1.31%	-4.94%
Debt / Equity	-	-	-	-	0.03x	0.04x	0.03x	0.83x	0.80x	0.84x
Interest Coverage	1758.08x	702.89x	-7.37x	30.48x	195.56x	56.00x	143.64x	-0.61x	0.22x	0.40x
FCF Conversion	1.22x	1.43x	2.25x	5.56x	1.01x	2.56x	2.59x	0.84x	-5.60x	-1.73x
Revenue Growth	10.48%	11.04%	240.72%	8.31%	-9.56%	0.38%	3.56%	73.21%	-0.92%	5.44%

Revenue by Segment

	2014	2015	2017	2018	2019	2020	2021	2022	2023	2024
Infusion Consumables	-	-	-	483.04M	477.61M	473.74M	555.19M	566.62M	969.13M	1.04B
Infusion Consumables Growth	-	-	-	-	-1.12%	-0.81%	17.19%	2.06%	71.04%	7.20%
Vital Care	-	-	-	-	-	-	-	284.61M	660.95M	690.77M
Vital Care Growth	-	-	-	-	-	-	-	-	132.23%	4.51%
Infusion Systems	-	-	-	355.48M	328.28M	359.69M	352.32M	351.08M	629.04M	652.41M
Infusion Systems Growth	-	-	-	-	-7.65%	9.57%	-2.05%	-0.35%	79.17%	3.71%
IV Solutions	-	-	-	507.99M	414.97M	388.97M	359.48M	363.47M	-	-
IV Solutions Growth	-	-	-	-	-18.31%	-6.27%	-7.58%	1.11%	-	-
Infusion Consumables-Smiths Medical	-	-	-	-	-	-	-	340.12M	-	-
Infusion Consumables-Smiths Medical Growth	-	-	-	-	-	-	-	-	-	-
Vascular Access	-	-	-	-	-	-	-	326.76M	-	-
Vascular Access Growth	-	-	-	-	-	-	-	-	-	-
Critical Care	-	-	-	53.53M	45.34M	48.6M	49.32M	47.33M	-	-
Critical Care Growth	-	-	-	-	-15.30%	7.19%	1.48%	-4.04%	-	-
Other Revenue	1.25M	1.16M	-	-	-	-	-	-	-	-
Other Revenue Growth	-	-7.33%	-	-	-	-	-	-	-	-
Sales Revenue, Net	-	341.67M	-	-	-	-	-	-	-	-
Sales Revenue, Net Growth	-	-	-	-	-	-	-	-	-	-
Infusion Therapy	215.98M	244.75M	-	-	-	-	-	-	-	-
Infusion Therapy Growth	-	13.32%	-	-	-	-	-	-	-	-
Critical Care Revenue	55.07M	54.31M	-	-	-	-	-	-	-	-
Critical Care Revenue Growth	-	-1.38%	-	-	-	-	-	-	-	-
Oncology Revenue	36.95M	41.45M	-	-	-	-	-	-	-	-
Oncology Revenue Growth	-	12.17%	-	-	-	-	-	-	-	-

Revenue by Geography

	2014	2015	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	979.94M	1.05B	923.34M	910.63M	941.81M	1.46B	1.44B	1.53B
UNITED STATES Growth	-	-	-	7.63%	-12.45%	-1.38%	3.42%	55.03%	-1.37%	6.39%
EMEA	-	-	-	134.36M	130.53M	132.76M	147.49M	367.41M	373.57M	393.53M
EMEA Growth	-	-	-	-	-2.85%	1.71%	11.09%	149.11%	1.68%	5.34%
Asia Pacific	-	-	54.47M	-	-	-	-	257.21M	241.7M	232M
Asia Pacific Growth	-	-	-	-	-	-	-	-	-6.03%	-4.01%
Other foreign countries	-	-	30.18M	211M	212.34M	227.61M	227.01M	195.31M	203.84M	223.59M
Other foreign countries Growth	-	-	-	599.03%	0.64%	7.20%	-0.26%	-13.96%	4.37%	9.69%
Foreign	-	-	312.68M	345.36M	342.87M	-	-	-	-	-
Foreign Growth	-	-	-	10.45%	-0.72%	-	-	-	-	-
Europe	-	-	100.42M	-	-	-	-	-	-	-
Europe Growth	-	-	-	-	-	-	-	-	-	-
CANADA	-	-	69.75M	-	-	-	-	-	-	-
CANADA Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

ICU Medical, Inc. (ICUI) reported $2.32B in revenue for fiscal year 2024. This represents a 668% increase from $302.2M in 2011.

ICU Medical, Inc. (ICUI) grew revenue by 5.4% over the past year. This is steady growth.

ICU Medical, Inc. (ICUI) reported a net loss of $7.4M for fiscal year 2024.

Dividend & Returns

ICU Medical, Inc. (ICUI) has a return on equity (ROE) of -5.8%. Negative ROE indicates the company is unprofitable.

ICU Medical, Inc. (ICUI) generated $67.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.